Company Overview

Aurora Cannabis Inc. is a Canadian cannabis company focused on the production, distribution, and commercialization of medical cannabis and consumer cannabis products. The company operates primarily in the regulated cannabis industry, with activities spanning cultivation, product development, manufacturing, and international distribution. Aurora generates revenue through medical cannabis sales, consumer recreational cannabis products, and international exports, with medical cannabis representing an increasingly significant portion of its business mix in recent years. Its product portfolio includes dried cannabis flower, oils, vapes, edibles, concentrates, and pharmaceutical-style medical cannabis products sold under multiple consumer and medical brands.

Aurora was founded in 2006 and became publicly traded in Canada before later listing on the Nasdaq under the ticker ACB. The company expanded aggressively during the early years of Canadian cannabis legalization through facility construction and acquisitions, including the acquisitions of CanniMed Therapeutics, MedReleaf, and Whistler Medical Marijuana Corporation. Following industry-wide oversupply and pricing pressure in the Canadian recreational market, Aurora shifted strategic focus toward higher-margin medical cannabis operations, international markets, and operational efficiency. The company positions itself through large-scale cultivation expertise, international medical cannabis infrastructure, and participation in regulated pharmaceutical-oriented cannabis markets.

Business Operations

Aurora conducts operations through two primary business channels: Global Medical Cannabis and Consumer Cannabis. The medical cannabis business includes production and distribution to patients and medical distributors in Canada, Europe, Australia, and other international jurisdictions where cannabis is federally regulated for medical use. The consumer cannabis segment focuses on the Canadian adult-use market through brands including Aurora Drift, San Rafael ’71, and Daily Special. Revenue is generated through wholesale and retail distribution agreements, direct-to-patient medical sales, and international exports.

The company operates cultivation and manufacturing assets primarily in Canada, including indoor cultivation facilities and processing operations designed to meet pharmaceutical-grade production standards. Aurora has maintained international distribution infrastructure and partnerships in markets such as Germany, Poland, Australia, and the United Kingdom. Its subsidiaries and affiliated operations have included Aurora Nordic in Denmark and various international medical distribution entities. Aurora has also invested in research initiatives related to cannabis genetics, cannabinoid extraction, and product formulation to support differentiated medical and consumer offerings.

Strategic Position & Investments

Aurora’s strategic direction has increasingly emphasized profitability, cash preservation, and expansion in international medical cannabis markets rather than large-scale recreational market share growth. Company filings and investor materials indicate that management has prioritized cost reductions, facility rationalization, and higher-margin medical cannabis sales following volatility across the Canadian cannabis sector. Aurora has continued investing in medical cannabis distribution capabilities in Europe and other federally regulated markets where pricing and reimbursement structures are generally more favorable than the Canadian recreational market.

Historically, Aurora pursued growth through acquisitions and strategic investments, including transactions involving CanniMed Therapeutics, MedReleaf, and Reliva LLC, a U.S.-based CBD company. The company has also participated in cannabis science and genetics development initiatives intended to strengthen product consistency and pharmaceutical positioning. Aurora’s strategic positioning has centered on regulatory compliance, international export capability, and participation in emerging medical cannabis frameworks. Data regarding the long-term commercial contribution of some prior investments and acquisitions remains mixed based on publicly available financial disclosures and evolving market conditions.

Geographic Footprint

Aurora Cannabis is headquartered in Edmonton, Alberta, Canada, and maintains operations and distribution activities across multiple international regions. Its primary operational footprint remains in Canada, where it cultivates, manufactures, and distributes both medical and recreational cannabis products. The company also maintains a significant presence in Europe, particularly through medical cannabis distribution channels in Germany, which has historically represented one of the largest federally regulated medical cannabis markets outside Canada.

Beyond North America and Europe, Aurora has reported commercial activity or distribution relationships in regions including Australia, Poland, and the United Kingdom. International operations have generally focused on medical cannabis exports and pharmaceutical distribution partnerships rather than direct recreational retail expansion. Aurora’s international footprint has been shaped by evolving cannabis regulations and export licensing frameworks, with strategic emphasis placed on federally legal medical markets.

Leadership & Governance

Aurora Cannabis has undergone multiple leadership transitions as the cannabis industry matured and market conditions changed. The company’s governance structure includes an executive leadership team and board oversight focused on operational discipline, international expansion, and long-term profitability. Public filings and investor communications indicate management emphasis on medical cannabis leadership, sustainable revenue growth, and disciplined capital allocation.

Key executives have included:

• Miguel Martin – Executive Chairman and former Chief Executive Officer
• Jill Lau – Chief Financial Officer
• Geoff Hoover – Senior Vice President, Commercial
• Andre Jerome – Executive Vice President, Global Business Development
• Simon St-Laurent – President, Aurora Europe

Aurora was co-founded by Terry Booth and Steve Dobler, both of whom played major roles during the company’s early expansion phase. Leadership strategy in recent years has focused on operational efficiency, international medical cannabis growth, and strengthening balance sheet performance amid changing industry conditions.